tbuckley/cabot-search huggingface dataset:
Burns and frostbite in the Red Army during World War II
Authors: Vladimir Sokolov, Alexey Biryukov, Igor Chmyrev, Mikhail Tarasenko, Pavel Kabanov
Journal: Military Medical Research (2017)

The start of World War II (WWII) led to the deployment of combat troops in several continents. Destruction and many casualties among both the military and civilians became an inevitable consequence. A large amount of people injured were in need of life-saving treatment and a speedy return to duty. Intensive studies of the specific issues of diagnosis and treatment of thermal injury were conducted in the Soviet Union before the war. The first special units for patients with burn injuries were created, and the first specialists received their first clinical experience. The contributions of famous Soviet scientists in the development of the treatment of burns and frostbite in WWII are studied in this article. The structure of thermal injuries among military personnel and the results of their treatment are shown. Treatment, classification and quantity frostbite in the structure of sanitary losses during the WWII are studied in this article.
Inherited Perforin and Fas Mutations in a Patient with Autoimmune Lymphoproliferative Syndrome and Lymphoma.
Authors: Rita Clementi, Lorenzo Dagna, Umberto Dianzani, Loic Dupre, Irma Dianzani, Fabio Ciceri, Rita Maccario, Franco Locatelli, Cesare Danesino, Marina Ferrarini, Marco Bregni
Journal: Blood (2004)
261P Efficacy of chemotherapy in patients with unresectable or metastatic pancreatic acinar cell carcinoma: Potentially improved efficacy with oxaliplatin-containing regimen
Authors: J. Cheon, C. Yoo, B. Kim, K-P. Kim, J-L. Lee, T.W. Kim, B-Y. Ryoo, H-M. Chang
Journal: Annals of Oncology (2016)
Epigenomic Analysis of Acute Myeloid Leukemia Identifies Specific Patterns and Markes with Clinical and Biological Relevance.
Authors: Sara Alvarez, Javier Suela, Ana Valencia, Agustin Fernandez, Mark Wunderlich, Xabier Agirre, Felipe Prosper, Jose Ignacio Martin-Subero, Alba Maiques, Francesco Acquadro, Sandra Rodriguez-Perales, Maria J. Calasanz, Jose Roman-Gomez, Reiner Siebert, James C. Mulloy, José Cervera, Miguel A. Sanz, Manel Esteller, Juan C Cigudosa
Journal: Blood (2009)
Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer (SCLC): Final results.
Authors: Neelesh Sharma, Nathan A. Pennell, Balazs Halmos, Patrick C. Ma, Afshin Dowlati
Journal: Journal of Clinical Oncology (2012)

e17563 Background: Sorafenib (S) is a small molecule multi-tyrosine kinase inhibitor of Raf kinase, VEGFR, and PDGFR. Angiogenesis is important for growth and progression of SCLC. This trial was conducted to evaluate whether the combination of cisplatin (P) and etoposide (E) plus concurrent and sequential S could prolong survival at one year in patients (pts) with previously untreated SCLC. Methods: Previously untreated pts with extensive stage SCLC, with ECOG 0-2 and adequate organ function were treated with P 60 mg/m2 day 1, E 120 mg/m2 days 1, 2, 3 x 4 cycles, concurrent with S 200 mg orally bid starting day 1 cycle 1. Pts with no disease progression after 4 cycles continued S 400 mg orally bid as maintenance for maximum of 12 months or until unacceptable toxicity, disease progression or withdrawal from the study. The primary endpoint was one year survival with response rate and safety of the combination as secondary endpoints. Total accrual of 28 pts from 3 centers was planned. Response and progression were monitored by CT’s every 8 week using RECIST criteria. Results: 12 and 17 pts were evaluable for response and adverse effects (AEs) respectively. Median age was 63 years (range 45 to 82), 9 pts (53%) were male. One pt had CR, 7 pts had PR and 1 pt had stable disease with an overall response rate of 67%. Overall median survival was 7.4 months and 1 year survival among response evaluable pts was 25%. The most common treatment-related adverse events included fatigue, anorexia, rash, diarrhea, neutropenia and weight loss. Grade 5 GI bleeding, pulmonary hemorrhage and neutropenia occurred in one pt (5%) each. Grade 4 events included neutropenia: 8 pts (47%), pneumonitis, thrombocytopenia and hypocalcemia in one pt each. Grade 3 events included supraventricular tachycardia: 2 pts (11%), hypocalcaemia and hyponatremia in two pts each. Accrual was halted on the basis of safety profile as well as preliminary efficacy data. Conclusions: Although the combination of EP plus S has anti-tumor activity in patients with extensive stage SCLC, at the current dose levels, this combination has significant AEs, is unlikely to be superior to standard treatment and is not recommended for further study.
Potential factors influencing initial sorafenib dose selection in hepatocellular carcinoma (HCC): U.S. regional analysis of GIDEON.
Authors: Bilal Piperdi, Allen Lee Cohn, Anthony B. El-Khoueiry, Jean-Francois Geschwind, Pierre Michel Gholam, Parvez Mantry, Robert C. G. Martin, Brendan McGuire, Rebecca A. Miksad, Arun J. Sanyal, Alan Paul Venook, Svetlana Babajanyan, Alec Goldenberg
Journal: Journal of Clinical Oncology (2014)

304 Background: GIDEON is a global, prospective, noninterventional study to evaluate sorafenib (SOR) safety under real-life practice conditions. Here we examine potential factors that may have had an impact on initial SOR dose (ID) selection in the U.S. cohort of GIDEON. Methods: Patients (pts) with unresectable HCC who were candidates for systemic therapy and for whom a decision was made to treat with SOR were eligible for inclusion. ID choice was at physician discretion. Baseline characteristics were analyzed for their potential impact on the choice of ID. Adverse events (AEs) were evaluated by ID. All results are descriptive. Results: 563 pts were valid for safety. 54% of pts received the recommended ID of 800 mg/d, 35% received 400 mg/d, and 11% other (includes 100, 200, 600 mg/d. dose). Among pts who had an ID &lt;800 mg/d, 37% underwent a dose increase to 800 mg/d. ID did not appear to differ by baseline Child-Pugh or its components, BCLC stage, etiology, or body mass index. By ECOG performance status (PS), IDs of 800/&lt;800 mg/day were given as follows: PS ≤1: 55%/45%; PS ≥2: 44%/56%. By age, corresponding values were 57%/42% for &lt;75 yr; 33%/67% for ≥75 yr. The incidence of AEs was similar across dose levels (Table). Conclusions: Baseline liver function, tumor stage, and etiology did not seem to have an influence on ID selection. We observed a trend toward lower ID in pts with age ≥75 yr and PS ≥2. Despite differences in average daily dose and time on drug, the safety profile for each ID was similar and dose adjustments may have contributed. Additional analyses are being evaluated to assess these and other contributing factors. Clinical trial information: NCT00812175. [Table: see text]
Genomic and Transcriptomic Analyses Revealed Differences and Similarities Between T-Lbl and T-ALL .
Authors: Lara Mussolin, Katia Basso, Antonella Lettieri, Manisha Brahmachary, Giovanni Cazzaniga, Andrea Califano, Wei-Keat Lim, Giuseppe Basso, Andrea Biondi, Angelo Rosolen
Journal: Blood (2009)
Antibody-Secreting Cells Are Elevated in Nasal Polyps of Crswnp Patients and Correlate with Complement Activation
Authors: Scott Feldman, Griet A. Van Roey, Richard Kasjanski, Jung W. Yoon, Jason N. Chen, Lydia A. Suh, James Norton, Roderick G. Carter, Robert C. Kern, Kevin C. Welch, Stephanie S. Smith, Kathleen E. Harris, Anju T. Peters, Leslie C. Grammer, Whitney W. Stevens, Atsushi Kato, Robert P. Schleimer, Bruce K. Tan, Kathryn E. Hulse
Journal: Journal of Allergy and Clinical Immunology (2017)
EN2: A candidate antigen for the development of targeted therapies in ovarian cancer.
Authors: A. Michael, C. Riley, S. Bokaee, M. Denyer, H. S. Pandha, N. E. Annels
Journal: Journal of Clinical Oncology (2011)

e15528 Background: Ovarian cancer remains the most lethal gynaecologic tumour in the Western world. Stimulation of the immune system to consolidate response to chemotherapy can potentially be beneficial however so far none of the vaccination strategies have offered survival advantage. Thus identifying and targeting clinically relevant antigens for immunotherapy continues to be an important research strategy. We have evaluated Engrailed-2 (EN2) as a potential target for vaccine strategy. EN2 is a homeodomain-containing transcription factor with a multifunctional role in neural development. There is evidence that over-expression of EN2 protein maybe linked to tumour development. Methods: Ovarian cancer cell lines were analysed by FACS for EN2 cell surface expression. EN2 expression in ovarian cancer tissue arrays were done by immunohistochemistry. A serum analysis (ELISA) was done to evaluate the presence of antibodies to EN2 in ovarian cancer patients and age-matched controls. A set of potentially immunogenic HLA-A2 restricted epitopes from the EN2 protein was identified using a computer algorithm SYFPEITHI. These peptides have been tested on HLA-A2 positive ovarian cancer patients’ PBMC using an in vitro culture method. The specificity of these T cell lines was analysed against T2 target cells loaded with or without EN2 peptides Results: Cell surface expression of EN2 was observed in ovarian cancer cell lines OVCAR3, OV90, CaOV-3, ES-2 and SKOV-3 of which ES-2 and SKOV3 showed strong expression. EN2 was also present in approximately 80% of ovarian cancer tissues whereas EN-2 expression was very low (<10%) or absent in normal tissues. Out of the 67 ovarian cancer patients 20.9% (14/67) had antibodies against EN2 compared to 2.4% (1/42) of age-matched female controls. 4 of the identified EN2 epitopes were able to generate peptide specific cytotoxic T lymphocytes in the ovarian cancer patients tested. Conclusions: The over-expression and immunogenicity of EN2 in ovarian cancer makes it a credible antigen to exploit as a novel target for ovarian cancer immunotherapy.
Erythropoietin (Epo) Secreting Mesenchymal Stromal Cells and Autocrine Signalling Via the Epo Receptor. A Novel, Cell-Based Paracrine Epo Delivery System for Cardiovascular Therapy.
Authors: Ian B. Copland, Marc E. Jolicoeur, Marc-Antoine Gillis, Jessica Cuerquis, Nicoletta Eliopoulos, Borhane Annabi, Angelo Calderone, Jean-Francois Tanguay, Anique Ducharme, Jacques Galipeau
Journal: Blood (2007)
429TiP IMpower010: A Phase III trial investigating atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy (chemo) in patients (pts) with completely resected NSCLC
Authors: C. Zhou, N. Altorki, E. Vallieres, E. Felip, Y. Zuo, M. Howland, F. Xia, T. Hoang, A. Sandler, H. Wakelee
Journal: Annals of Oncology (2016)
High Incidence of EZH2 Mutations with Variable Mutation Load in Follicular Lymphoma and Its Consequences for EZH2 Targeted Therapy
Authors: Csaba Böodöor, Grossmann Vera, Alexander Kohlmann, King Tan, Jessica Okosun, Nikolay Popov, Shamzah Araf, Jacek Marzec, Ciaran O‘Riain, Abigail Lee, Andrew James Clear, Silvia Montoto, Janet Matthews, Sameena Iqbal, Hajnalka Rajnai, Andreas Rosenwald, German Ott, Elias Campo, Erlend B. Smeland, Wing C. Chan, Rita M. Braziel, Louis M. Staudt, George Wright, Lisa M. Rimsza, T. Andrew Lister, Olivier Elemento, John G Gribben, Andras Matolcsy, Torsten Haferlach, Randy D. Gascoyne, Jude Fitzgibbon
Journal: Blood (2012)
Experimental Bacteriology in Its Applications to the Diagnosis, Epidemiology, and Immunology of Infectious Diseases
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Emotional/psychological characteristics of women diagnosed with breast cancer following treatment: Participation versus nonparticipation in survivorship programs.
Authors: Kathleen Dickerson Swiger, Janine Guglielmino, Jeffrey D. Labban, Hope S. Rugo, Carey K. Anders, Arin Ahlum Hanson, Catherine Creme Henry
Journal: Journal of Clinical Oncology (2016)

216 Background: Women diagnosed with breast cancer responded to an 80-question online assessment to determine their education, information, and support needs. All responses were self-reported, including those about treatment stage, emotional/psychological characteristics, and level of emotion experienced. Methods: A total of 1,443 responses were analyzed. Responses from 776 women (53.8%) who reported participation in survivorship programs were compared to responses from 667 women (46.2%) who did not report participation. On a scale of none, low, moderate, or high, respondents rated the degree to which they experienced anxiety, fear, anger, worry, sadness, and confusion following treatment. Examination of histograms revealed that emotion ratings were not normally distributed. Therefore, differences in ratings between the two groups were tested using Mann-Whitney U analyses, a nonparametric alternative to the independent samples t-test. Results: Respondents who participated in survivorship programs reported significantly higher ratings of emotional experience for anxiety (p &lt; .001), fear (p = .004), worry (p = .002), sadness (p &lt; .001), and confusion (p = .005). A similar trend was observed for anger, which approached significance (p = .051). Overall, survivorship program participants reported more intense experiences of negative emotions following treatment than did non-participants. Conclusions: Self-referral to survivorship programs may reflect continued patient concerns about diagnosis and prognosis, offering insights into patient populations with greater need for support following completion of treatment. Availability of programs and heterogeneity of disease characteristics and treatment may impact these results. The difference in ratings supports the importance of continued monitoring and evaluation of the emotional/psychological needs of women diagnosed with breast cancer following treatment, and especially of those women participating in survivorship programs.
Variants in 15q22 Genomic Regions Associated with Atopy in an Admixed Population of Northeastern Brazil
Authors: Valdirene Leao Carneiro, Louise Correia Lima, Ryan Santos Costa, Cíntia Rodrigues Marques, Gustavo Nunes de Oliveira Costa, Neuza Maria Alcântara-Neves, Mauricio Lima Barreto, Camila Alexandrina Figueiredo
Journal: Journal of Allergy and Clinical Immunology (2017)
BMET-03. METIS: A PHASE III STUDY OF RADIOSURGERY WITH TTFIELDS FOR 1-10 BRAIN METASTASES FROM NSCLC
Authors: Minesh Mehta, Paul Brown, Vinai Gondi
Journal: Neuro-Oncology (2016)

Tumor Treating Fields (TTFields) are a novel, non-invasive regional anti-mitotic treatment modality, based on low intensity alternating electric fields. Efficacy of TTFields in non-small cell lung cancer (NSCLC) has been demonstrated in multiple in vitro and in vivo models, and in a phase I/II clinical study. TTFields treatment to the brain was shown to be safe and effective in glioblastoma patients. TRIAL DESIGN: 270 patients with 1-10 brain metastases (BM) from NSCLC will be randomized in a ratio of 1:1 to receive stereotactic radio surgery (SRS) followed by either TTFields or supportive care alone. Patients are followed-up every two months until second cerebral progression. Patients in the control arm may cross over to receive TTFields at the time of second cerebral progression. To test the efficacy, safety and neurocognitive outcomes of TTFields in this patient population. ENDPOINTS: Time to first cerebral progression (primary); time to neurocognitive failure; overall survival; radiological response rate; quality of life; adverse events severity and frequency (secondary). TREATMENT: Continuous TTFields at 150 kHz will be applied to the brain within 7 days of SRS. The treatment system is a portable medical device allowing normal daily life activities. Patients will receive the best standard of care for their systemic disease. The trial is designed to detect an increase in the time to cerebral progression from 7.7 to 13.4 months (hazard ratio 0.57). The sample size assessment takes into consideration a competing risk (death prior to cerebral progression) of 0.08252 per month in both treatment arms. The competing risk is based on a predicted median overall survival of 8.4 months mainly due to systemic disease progression. The trial has 80% power at a two sided alpha of 0.05. The sample size was calculated using a log-rank test (based on Lakatos 1988 and 2002).
Chromosome 21 Encoded RUNX1 and ETS-2 Overexpression in Regenerating Hematopoiesis in Children with Down Syndrome - Implications for Leukemiogenesis?.
Authors: Dirk Reinhardt, Kristin Wortmann, Miriam Kolar, Jan H. Klusmann, Ulrike Puhlmann, Jean P. Bourquin, Ursula Creutzig, Claudia Langebrake
Journal: Blood (2005)
Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: Results of a randomized double-blind placebo-controlled study with intensified COP-BLAM ± rhGM-CSF
Authors: M Engelhard, H Gerhartz, G Brittinger, A Engert, R Fuchs, B Geiseler, D Gerhartz, A R Haunauske, H J Hartlapp, D Huhn
Journal: Annals of Oncology (1994)
Age-Specific Trends in Incidence, Mortality, and Comorbidities of Heart Failure in Denmark, 1995 to 2012
Authors: Mia N. Christiansen, Lars Køber, Peter Weeke, Ramachandran S. Vasan, Jørgen L. Jeppesen, J. Gustav Smith, Gunnar H. Gislason, Christian Torp-Pedersen, Charlotte Andersson
Journal: Circulation (2017)

Background: The cumulative burden and importance of cardiovascular risk factors have changed over the past decades. Specifically, obesity rates have increased among younger people, whereas cardiovascular health has improved in the elderly. Little is known regarding how these changes have impacted the incidence and the mortality rates of heart failure. Therefore, we aimed to investigate the age-specific trends in the incidence and 1-year mortality rates following a first-time diagnosis of heart failure in Denmark between 1995 and 2012. Methods: We included all Danish individuals &gt;18 years of age with a first-time in-hospital diagnosis of heart failure. Data were collected from 3 nationwide Danish registries. Annual incidence rates of heart failure and 1-year standardized mortality rates were calculated under the assumption of a Poisson distribution. Results: We identified 210 430 individuals with a first-time diagnosis of heart failure between 1995 and 2012; the annual incidence rates per 10 000 person-years declined among older individuals (rates in 1995 versus 2012: 164 versus 115 in individuals &gt;74 years, 63 versus 35 in individuals 65–74 years, and 20 versus 17 in individuals 55–64 years; P &lt;0.0001 for all) but increased among the younger (0.4 versus 0.7 in individuals 18–34 years, 1.3 versus 2.0 in individuals 35–44 years, and 5.0 versus 6.4 in individuals 45–54 years; P &lt;0.0001 for all). The proportion of patients with incident heart failure ≤50 years of age doubled from 3% in 1995 to 6% in 2012 ( P &lt;0.0001). Sex- and age-adjusted incidence rate ratios for 2012 versus 1996 were 0.69 (95% confidence interval, 0.67–0.71; P &lt;0.0001) among people &gt;50 years of age, and 1.52 (95% confidence interval, 1.33–1.73; P &lt;0.0001) among individuals ≤50 years of age; it remained essentially unchanged on additional adjustment for diabetes mellitus, ischemic heart disease, and hypertension. Standardized 1-year mortality rates declined for middle-aged patients with heart failure but remained constant for younger (&lt;45 years) and elderly (≥65 years) patients. The prevalence of comorbidities (including diabetes mellitus, hypertension, and atrial fibrillation) increased, especially in younger patients with heart failure. Conclusions: Over the past 2 decades, the incidence of heart failure in Denmark declined among older individuals (&gt;50 years), but increased among younger (≤50 years) individuals. These observations may portend a rising burden of heart failure in the community.
BCR-ABL1 Kinase Inhibits DNA Glycosylases to Enhance Oxidative DNA Damage and Stimulate Genomic Instability
Authors: Artur Slupianek, Rafal Falinski, Pawel Znojek, Tomasz Stoklosa, Sylwia Flis, Valentina Doneddu, Ewelina Synowiec, Janusz Blasiak, Alfonso Bellacosa, Tomasz Skorski
Journal: Blood (2012)
Immunotherapy and Chemotherapy Can Result in Long-Term Survival for Patients with Recurrent or Progressive Non-Hodgkin’s Lymphoma after Reduced-Intensity Allogeneic Stem Cell Transplantation.
Authors: Michael R. Bishop, Robert M. Dean, Wyndham H. Wilson, Jeanne Odom, Seth Steinberg, Michael Krumlauf, Claude Kasten-Sportes, Steven Z. Pavletic, Kathleen Castro, Tracey Chinn, Ronald Gress, Daniel H. Fowler
Journal: Blood (2004)
512P VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma
Authors: J.Y. Moon, S.-W. Baek, H. Ryu, Y.S. Choi, I.-C. Song, H.-J. Yun, D.-Y. Jo, S. Kim, H.J. Lee
Journal: Annals of Oncology (2016)
Unique Resistance Mechanism to Dexamethasone by Glutathione S-Transferase M1 Involving p38 MAPK and NF-κB Pathways, Possible Prognostic Role for Childhood ALL.
Authors: Naoko Hosono, Shinji Kishi, Sumiko Iho, Yoshimasa Urasaki, Akira Yoshida, Hisanori Kurooka, Yoshifumi Yokota, Takanori Ueda
Journal: Blood (2007)
Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993)
Authors: Jacob M. Rowe, Georgina Buck, Anthony V Moorman, Martin S Tallman, Susan M Richards, Adele K Fielding, Alan K. Burnett, Ian M Franklin, Peter H. Wiernik, Hillard M Lazarus, Elisabeth Paietta, Mark R. Litzow, David I Marks, Selina Luger, Gordon W. Dewald, Anthony H. Goldstone
Journal: Blood (2008)